Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 6,059 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer

NCT07759921
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Colorectal Cancer (CRC)
Interventions
Couple-based Mindfulness Intervention, Health and Wellness Education Control Condition
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

NCT01406548
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 19, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Riociguat in Scleroderma Associated Digital Ulcers

NCT02915835
View directory record Official record
Conditions
Scleroderma, Digital Ulcers
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01314716
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

NCT04386616
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
MSTT1041A, MSTT1041A-matched Placebo, UTTR1147A, UTTR1147A-matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Little Rock, Arkansas • Chula Vista, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

NCT05075408
View directory record Official record
Conditions
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
47
States / cities
Bakersfield, California • Glendale, California • La Palma, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

NCT04247815
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450, Placebo oral tablet, Methotrexate
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Anniston, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

NCT03815825
View directory record Official record
Conditions
Macular Degeneration, Geographic Atrophy
Interventions
IONIS-FB-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
55
States / cities
Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 19, 2026, 2:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

NCT07842640
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Terminated Phase 4 Interventional Results available

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

NCT01250496
View directory record Official record
Conditions
Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 19, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

NCT04641962
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
Bocidelpar, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
La Jolla, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 19, 2026, 2:30 PM EDT
Completed No phase listed Observational Results available

TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD

NCT01043705
View directory record Official record
Conditions
Cardiac Implantable Electronic Device Infection
Interventions
Not listed
Lead sponsor
TYRX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
52
States / cities
Birmingham, Alabama • Decatur, Alabama • Florence, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Correcting Residual Errors With Spectral, Ultrasound, Traditional Speech Therapy

NCT03737318
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Biofeedback-ultrasound, Biofeedback--visual-acoustic, Traditional articulation treatment
Behavioral
Lead sponsor
New York University
Other
Eligibility
9 Years to 15 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Bloomfield, New Jersey • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

NCT06311760
View directory record Official record
Conditions
Healthy Participants Study
Interventions
AZD0292, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 19, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

NCT03600805
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 19, 2026, 2:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching placebo
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
58
States / cities
Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

NCT06136546
View directory record Official record
Conditions
Depressive Disorder, Major, Inflammation
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

NCT02534038
View directory record Official record
Conditions
Disinhibition Syndrome
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677543
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cycling, Running, and Playing Rugby on Three Biomarkers That May Indicate Brain Injury

NCT06804291
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Running, Cycling, Rugby, control group
Other
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis

NCT03595618
View directory record Official record
Conditions
Osteoarthritis
Interventions
GLPG1972, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years to 75 Years
Enrollment
932 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 19, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients

NCT00958997
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
18F-FP-DTBZ (18F-AV-133), Arginine-hydrochloride
Drug · Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 19, 2026, 2:30 PM EDT